Biosplice News and Activities
Presence
Biosplice is a biotechnology company that develops regenerative medicine and cancer treatments. Its main products and services are drug candidates and clinical research for patients, healthcare providers, and research partners.
Biosplice products and services overview:
- Regenerative medicine
- Cancer therapies
- Clinical research
- Drug development
- Pipeline programs
Revenue: ~$0 million
Employees: 250
Headquarters: San Diego, United States (USA)
Biosplice is one of the...
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Biosplice
- Erich Horsley, Chief Executive Officer
- Finian Tan, Director
- Osman Kibar, Executive Chairman of the Board
Create your alert
to follow the executive moves at Biosplice.
Biotechnology
Biosplice has 2,414 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).
Popular M&A news in Biotechnology
- Nura Bio has just announced a $74 Million fundraising (posted on June 22 2026).
- Memento Medicines has just announced a $93 Million fundraising (posted on June 22 2026).
- Alvotech has just announced a $165 Million fundraising (posted on June 19 2026).
Popular contacts in Biotechnology
News
Press releases by Biosplice
- Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
- Biosplice Therapeutics Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum‑Resistant Ovarian Cancer
- Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
- Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
- Biosplice Announces Collaboration with Novo Nordisk in Diabetes
- Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week
- Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
- Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
- Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
- View more press releases Close
Social media about Biosplice
- Biosplice on Wikipedia, Google News & Yahoo Finance
- Biosplice on LinkedIn, X (Twitter) & YouTube
